ABIRATRAL

Active ingredients

The drug ABIRATRAL contains one active pharmaceutical ingredient (API):

UNII EM5OCB9YJ6 - ABIRATERONE ACETATE

Abiraterone acetate is converted in vivo to abiraterone, an androgen biosynthesis inhibitor. Specifically, abiraterone selectively inhibits the enzyme 17α-hydroxylase/C17,20-lyase (CYP17). This enzyme is expressed in and is required for androgen biosynthesis in testicular, adrenal and prostatic tumour tissues. CYP17 inhibition also results in increased mineralocorticoid production by the adrenals.

Read about Abiraterone

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code
Group title
Classification
L02BX03
Abiraterone
L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02B Hormone antagonists and related agents → L02BX Other hormone antagonists and related agents
Discover more medicines within L02BX03

Authorization and marketing

This brand name is authorized in the following countries: Ecuador

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country
Identification scheme
Identifier(s)
EC
Agencia Nacional de Regulación, Control y Vigilancia Sanitaria
Identifier(s): 2881-MEE-0617